Authorisation to decide on the repurchase of the Company’s shares
The Annual General Meeting held on 20 March 2025 authorised the Board of Directors to decide on the repurchase of a maximum of 300,000 shares, which corresponds to approximately 7.6% of the current total number of shares in the company. However, the Company, together with its subsidiaries, may not own and/or pledge more than 10% of all the shares in the Company at any time. Under the authorisation, own shares may only be acquired with free equity.
The shares may be acquired at the price prevailing in multilateral trading on the day of acquisition or at any other market price. Shares may also be acquired in the open market at a price not exceeding the market price in the open market at the time of acquisition.
The Board of Directors decides how the shares are to be acquired. Own shares may be acquired otherwise than in proportion to the shares held by the shareholders (directed acquisition) if there is a weighty economic reason for the company to do so in accordance with Chapter 15, Section 6 of the Companies Act.
Own shares may be acquired for the purpose of developing the company's capital structure , for the purpose of developing the company's capital structure, for transfer for the purpose of financing or implementing possible acquisitions, investments or other arrangements relating to the company's business, for use in the company's incentive schemes or otherwise for further transfer, retention or annulment.
The authorisation annuls the authorisation granted by the Annual General Meeting of 20 March 2024. The authorisation is valid until the next Annual General Meeting, but not later than 30 June 2026.
Authorisation to issue shares, option rights and other special rights entitling to shares
The Annual General Meeting held on 20 March 2025 authorised the Board of Directors to decide on the share issue and the issue of warrants and other special rights entitling to shares referred to in Chapter 10, Section 1 of the Companies Act in one or more tranches as follows:
A maximum of 390,000 shares (including shares to be issued on the basis of special rights) may be issued on the basis of the authorisation, which corresponds to approximately 9.9% of the current number of all shares in the company.
The Board of Directors will decide on the terms and conditions of the share issue and of the issue of warrants and other special rights entitling to shares. Under the authorisation, both new shares and shares held by the company may be issued. New shares may be issued and shares held by the company may be transferred either against payment or free of charge. The issue and transfer of shares, option rights and other special rights entitling to shares may be effected by way of derogation from the shareholders' pre-emptive subscription rights (directed issue) if there are weighty economic reasons from the company's point of view, such as the use of the shares for the purpose of developing the company's capital structure, for possible acquisitions, investments or other arrangements relating to the company's business or for the implementation of the company's commitment and incentive schemes. The Board of Directors may also decide on a share issue free of charge to the company itself.
The authorisation annuls the authorisation granted by the Annual General Meeting of 20 March 2024. The authorisation is valid until the next Annual General Meeting, but not later than 30 June 2026.